Bristol Myers Squibb (NYSE:BMY) Given New $64.00 Price Target at Citigroup

Bristol Myers Squibb (NYSE:BMY) had its price objective increased by investment analysts at Citigroup from $60.00 to $64.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Citigroup’s target price indicates a potential upside of 3.41% from the company’s current price.

A number of other equities analysts also recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and issued a $66.00 target price (up previously from $62.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 28th. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price objective (up previously from $55.00) on shares of Bristol Myers Squibb in a research note on Friday. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price target for the company from $52.00 to $61.00 in a report on Monday, December 15th. Finally, Scotiabank reiterated a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $59.20.

Bristol Myers Squibb Trading Up 4.0%

Bristol Myers Squibb stock traded up $2.37 during midday trading on Friday, reaching $61.89. The stock had a trading volume of 10,517,312 shares, compared to its average volume of 13,284,006. The firm’s fifty day simple moving average is $54.08 and its two-hundred day simple moving average is $48.92. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $63.33. The firm has a market cap of $126.00 billion, a price-to-earnings ratio of 20.87, a PEG ratio of 0.18 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter in the previous year, the company earned $1.67 EPS. Bristol Myers Squibb’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts anticipate that Bristol Myers Squibb will post 6.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Gateway Investment Advisers LLC raised its position in shares of Bristol Myers Squibb by 10.0% during the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after purchasing an additional 10,284 shares during the period. CWA Asset Management Group LLC increased its stake in Bristol Myers Squibb by 25.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after purchasing an additional 30,909 shares in the last quarter. Commonwealth Retirement Investments LLC raised its holdings in Bristol Myers Squibb by 24.6% during the 2nd quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock worth $2,740,000 after buying an additional 11,690 shares during the period. Railway Pension Investments Ltd lifted its stake in Bristol Myers Squibb by 3.7% in the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after buying an additional 40,300 shares in the last quarter. Finally, Stephens Inc. AR increased its position in shares of Bristol Myers Squibb by 13.5% during the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after acquiring an additional 32,476 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q4 revenue beat estimates ($12.5B vs. ~$12.24B) and the company’s Growth Portfolio showed mid-teens organic growth, which investors view as offsetting declines in older drugs. Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management issued an upbeat FY‑2026 outlook (EPS $6.05–$6.35; revenue $46.0–$47.5B) that sits above many Street revenue expectations and signals confidence that a planned Eliquis price cut will expand volume/revenue in 2026. Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off
• Positive Sentiment: Management (CEO) emphasized the strongest pipeline in years and new growth engines (including recent manufacturing/partnering moves), reinforcing expectations for sustained medium‑term growth. Bristol Myers Squibb CEO: Richest product pipeline we’ve had in the last decade
• Neutral Sentiment: Some outlets note BMY expects sales to decline this year on a reported basis (mix and pricing moves), yet the stock is rallying because guidance and margin/volume assumptions imply better adjusted results — investors are weighing accounting/volume effects vs. operational strength. Bristol Myers expects sales to decline this year; so why is the stock rising?
• Neutral Sentiment: Broader macro headlines (weekly jobless claims) are mixed this morning and create market-wide volatility but don’t materially change BMY’s company-specific narrative. Weekly Jobless Claims Exceed Expectations
• Negative Sentiment: GAAP/non‑GAAP EPS dynamics are noisy — Q4 non‑GAAP EPS was $1.26 (down from $1.67 year‑ago) and some metrics disappointed certain consensus prints, which underscores ongoing pressure from legacy product declines. Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Legacy drug declines remain a headwind and will require sustained Growth Portfolio momentum and successful Eliquis volume conversion to fully replace lost sales; execution risk remains. Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: Strong Growth in New Products …

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.